Your SlideShare is downloading. ×
European Policy Actions
 Cooperation in the field of Rare Diseases
“Share an inspired vision in rare diseases”


         ...
EU Orphan drug policy – an ongoing process


 1999 – EU’s Orphan Regulation adopted
 2001 – First Orphan product authori...
Results


Recommendation & Commission Communication

 National Rare Disease         EU proposals on access,
Plans in all E...
A result of collaborative action

                    European Commission




                    Rare Disease Community

...
Why is this important?


 Issues of key importance to the whole rare disease
  community
 Proposed fundamental changes t...
What did we
               already do together to get here?

   Internal engagement
     •   Internal conversations
     ...
EU Orphan drug policy – an ongoing process


 1999 – EU’s Orphan Regulation adopted
 2001 – First Orphan product authori...
What remains to be done?


 Stimulate / engage in lobbying at country level on
  National Plans
  => 8-9 June 2009: ACTIO...
National Plans for Rare Diseases – 2009 onwards


Recommendation

 National Rare Disease
Plans in all EU countries
    8-9...
National Plans for Rare Diseases 2009-2014


   What could be in an ideal National Plan?
   Multi-stakeholder committee ...
Cooperation – National Plans

               Council Recommendation
             (& Commission Communication)
            ...
Results – 2009 and next 5 years…


                    Commission Communication

                        EU proposals on a...
European Commission Communication
on “Rare Diseases – Europe’s Challenges”

1. (Introduction / background)
2. Improve poli...
Facilitating Access / Conditional Reimbursement



       Council                           Commission
   Recommendation  ...
Eurordis & Nord working together
International Cooperation


 Regions cooperating to share
 But also learning from experience
 International forum:
   •...
2009 – a year of change at European level

 Commission & Parliament will change
  • Some dossiers have been postponed
  •...
What remains to be done?

 Stimulate / engage in lobbying at country level on
  National Plans
 Engage with European aut...
10th Cooperative Policy-Making Forum
= EPPOSI = Patients + Science + Industry


            www.epposi.org
Conclusions?

•   There is a lot happening. And a lot of opportunities to
    directly affect the outcome!
•   Cooperation...
THANK YOU!


wills.hughes-wilson@genzyme.com
          +32 2 714 1743
Wills Hughes Wilson
Wills Hughes Wilson
Wills Hughes Wilson
Wills Hughes Wilson
Upcoming SlideShare
Loading in...5
×

Wills Hughes Wilson

998

Published on

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
998
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Transcript of "Wills Hughes Wilson"

  1. 1. European Policy Actions Cooperation in the field of Rare Diseases “Share an inspired vision in rare diseases” Wills Hughes-Wilson Health Policy Europe, Genzyme Cluj, 26 June 2009 Balkans Congress for Rare Diseases
  2. 2. EU Orphan drug policy – an ongoing process  1999 – EU’s Orphan Regulation adopted  2001 – First Orphan product authorised in EU  2003 – Eurordis survey: “issues remain”…  2005 – 2nd Eurordis survey: “issues still remain!”  2005 – Eurordis calls for action to address  2007 – First draft of an EU policy document appears  2008 – Public consultations  2009 – EU Communication & Recommendation!
  3. 3. Results Recommendation & Commission Communication National Rare Disease EU proposals on access, Plans in all EU countries NBS, Compassionate Use… 8-9 June 2009(?) 2009 onwards… Political commitment Mechanisms & machinery at country level at EU level ACTION: ACTION: Needed at government Needed at both level in each country (1) EU / Commission level & (2) Coordinated country action(s)
  4. 4. A result of collaborative action European Commission Rare Disease Community Member Member Member Member Member Member State State State State State State
  5. 5. Why is this important?  Issues of key importance to the whole rare disease community  Proposed fundamental changes to EU approach to diagnosis, treatment and care for rare diseases  Work done – internal & external  Where are we now? And where next?
  6. 6. What did we already do together to get here?  Internal engagement • Internal conversations • Messaging, process & engagement – countries • Training & workshops • Programme of meetings  Outputs • Internal positioning – deciding what is key? • External positioning • Delivering the messages  External engagement • Other stakeholders • Decision-makers: EU Commission, EMEA & Member States
  7. 7. EU Orphan drug policy – an ongoing process  1999 – EU’s Orphan Regulation adopted  2001 – First Orphan product authorised in EU  2003 – Eurordis survey: “issues remain”…  2005 – 2nd Eurordis survey: “issues still remain!”  2005 – Eurordis calls for action to address  2007 – First draft of an EU policy document appears  2008 – Public consultations  2009 – EU Communication & Recommendation!
  8. 8. What remains to be done?  Stimulate / engage in lobbying at country level on National Plans => 8-9 June 2009: ACTION  Engage with European Commission • Conditional reimbursement • Other actions: NBS, Registries, etc.  What is happening? When? Opportunities to engage?  Identify goals / objectives in engagement • Focus & priorities • Roles & responsibilities
  9. 9. National Plans for Rare Diseases – 2009 onwards Recommendation National Rare Disease Plans in all EU countries 8-9 June 2009(?) Political commitment at country level ACTION: Needed at government level in each country
  10. 10. National Plans for Rare Diseases 2009-2014  What could be in an ideal National Plan?  Multi-stakeholder committee – tailor the plans  Toolkit – “what’s happening in other countries?”  Lobbying essential at country level  Collaboration at country level  National Rare Disease Days 2010
  11. 11. Cooperation – National Plans Council Recommendation (& Commission Communication) Adopted June 2009 “NATIONAL RARE DISEASE PLANS” – 2011 Cooperative efforts, e.g., “Europlan” Member Member Member Member Member Member State State State State State State
  12. 12. Results – 2009 and next 5 years… Commission Communication EU proposals on access, NBS, Compassionate Use… 2009 onwards… Mechanisms & machinery at EU level ACTION: Needed at both (1) EU / Commission level & (2) Coordinated country action(s)
  13. 13. European Commission Communication on “Rare Diseases – Europe’s Challenges” 1. (Introduction / background) 2. Improve political recognition 3. Recognition & visibility of RD 4. European Cooperation & Improve Access to Quality Healthcare 5. International Cooperation – ICORD, NIH, WHO 6. Governance & Monitoring
  14. 14. Facilitating Access / Conditional Reimbursement Council Commission Recommendation Communication Rare Disease National Plans EU proposals Art. 5(1)(c) Art. 5(3) “Member States to “European Commission cooperate on to set up a Working Party Common Assessment Reports with Member States & Clinical / Therapeutic EU authorities on the Added Value of orphan drugs” scientific assessments of clinical added value of orphan drugs”
  15. 15. Eurordis & Nord working together
  16. 16. International Cooperation  Regions cooperating to share  But also learning from experience  International forum: • World Health Organisation • ICH – International (regulatory) harmonisation efforts • ICORD – International Conference on Rare Diseases • What is in an ideal national plan? • What is the minimum a government needs to do?  Bringing ideas, experience – do not all need to start from the beginning any more!
  17. 17. 2009 – a year of change at European level  Commission & Parliament will change • Some dossiers have been postponed • But not rare diseases!  Re-appointment of European Commission • New work plans & focus? • Engagement now & friends!  European Parliament elections • New dossiers, new responsibilities • Build new contacts
  18. 18. What remains to be done?  Stimulate / engage in lobbying at country level on National Plans  Engage with European authorities & stakeholders  What is happening? When? Opportunities to engage?  Identify goals / objectives in engagement • Focus & priorities AND • Roles & responsibilities
  19. 19. 10th Cooperative Policy-Making Forum = EPPOSI = Patients + Science + Industry www.epposi.org
  20. 20. Conclusions? • There is a lot happening. And a lot of opportunities to directly affect the outcome! • Cooperation is essential. We cannot be successful without cooperation • Objective = to achieve the best outcome for the rare disease community • We have achieved a lot together already! THE FUTURE? Where do we go from here? How can we work together to be successful?
  21. 21. THANK YOU! wills.hughes-wilson@genzyme.com +32 2 714 1743

×